To address this knowledge gap, we analyzed SARS-CoV-2–specific CD4+ and CD8+ T cells among pediatric participants with MIS-C, COVID-19 (1–2 months after symptom onset), and healthy children (HC). This evidence concerns the gene CD4 and COVID-19.